Skip to main content

Strides Pharma Science Limited (STAR.NS)

National Stock Exchange of India Healthcare Drug Manufacturers - Specialty & GenericView data quality →
50.8Fair

ValueMarkers Composite Index

Top 32%#30,496 of 44,714
Overvalued

256% above intrinsic value ($3)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-2.27
Low Risk
Altman
2.83
Grey Zone
DCF Value
$3
Overvalued
ROIC
12.1%
Adequate
P/E
18.0
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Strides Pharma Science Limited (STAR.NS) — VMCI valuation read

Headline read on STAR.NS: VMCI of 51/100 versus a Healthcare sector median of 50. The 1-point above-median position is what makes Strides Pharma Science Limited a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on STAR.NS: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on STAR.NS: value (STAR.NS trades at 15.0x earnings, 17% below the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 0.1x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

STAR.NS rose 3.4% over the trailing 7 days, with a -1.3% read on a 30-day basis.

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

CEO: Badree Komandur3,065 employeesINwww.strides.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in STAR.NS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.